PPARγ maintains ERBB2-positive breast cancer stem cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• ERBB2-positive breast cancer is aggressive and linked to poor outcomes.
• NR1D1 and PBP regulate de novo fatty acid synthesis genes in these cells.
• The peroxisome proliferator-activated receptor-γ (PPARγ) pathway is implicated in lipid metabolism and adipogenesis.

Purpose of the Study:

• To investigate the role of the PPARγ pathway in ERBB2-positive breast cancer stem cells.
• To determine if PPARγ antagonists can inhibit cancer stem cell properties.

Main Methods:

• Utilized in vitro tumorsphere formation assays with ERBB2-positive breast cancer cells.
• Administered PPARγ antagonists (GW9662, T0070907) and measured effects on ALDH-positive cells and tumorsphere formation.
• Conducted gene expression analysis and assessed histone acetylation levels.
• Performed in vivo tumor-seeding assays.

Main Results:

• PPARγ pathway inhibition reduced the aldehyde dehydrogenase (ALDH)-positive population and tumorsphere formation in ERBB2-positive cells.
• GW9662 treatment suppressed lipogenic and stem-cell related genes (ACLY, FASN, NR1D1, KLF4, ALDH).
• Antagonist treatment decreased histone 3 and histone 4 acetylation and inhibited tumor-seeding ability in vivo.

Conclusions:

• The PPARγ pathway is crucial for maintaining cancer stem cell characteristics in ERBB2-positive breast cancer.
• Targeting the PPARγ pathway represents a potential therapeutic strategy for this subtype of breast cancer.